Drug Profile
Research programme: metabolic disorders therapy - DeveloGen
Alternative Names: DG 70 inhibitors; DG070 inhibitorsLatest Information Update: 27 Sep 2019
Price :
$50
*
At a glance
- Originator DeveloGen
- Developer DeveloGen; Evotec SE
- Class Small molecules
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Metabolic syndrome; Obesity; Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Metabolic-syndrome in Germany (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in Germany (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Germany (PO)